Immune Protection Technologies for Cell Therapy
ImmunoShield develops cell encapsulation and immune tolerance technologies designed to reduce rejection and expand patient access to cell therapy, starting with Type 1 Diabetes.
Expanding Access to allogeneic cell therapy
Cell therapies have the potential to cure diseases, but immune rejection limits access to only 20% of patients. ImmunoShield is developing technologies to address this barrier, expanding the market 5x and making breakthrough treatments available to millions.
-
The Problem
80% of patients are excluded from cell therapies due to dangerous immune suppression drugs.
-
Our Solution
Our platform is designed to protect therapeutic cells from immune attack while preserving function.
-
Expert Team
15+ years of cell therapy expertise with proven track record in commercialization.
Investment Opportunity
Seeking pre-seed investment to complete large animal studies and position for strategic pharma partnerships. Backed by $1.8M NIH SBIR award and partnerships with leading institutions.
- 5.5xMarket expansion potential
- $1.8MNIH funding secured
- TRL 4Technology readiness
-
80%
Patients currently excluded
-
$18.3B
Cell therapy market size
-
27%
Annual growth rate
-
20+
Industry interviews